Yoshiyuki Taoda

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Lassa fever and Argentine hemorrhagic fever treatment in guinea pigs using broad-spectrum cap-dependent endonuclease inhibitors.

Lassa fever and Argentine hemorrhagic fever treatment in guinea pigs using broad-spectrum cap-dependent endonuclease inhibitors.

Journal: mBio

Published: August 17, 2026

Optimization of pyridopyrimidinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.

Optimization of pyridopyrimidinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 30, 2026

A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection.

A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection.

Journal: Antimicrobial agents and chemotherapy

Published: July 23, 2025

Design, synthesis and biological evaluation of novel quinazolinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.

Design, synthesis and biological evaluation of novel quinazolinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: July 19, 2025

Design, Synthesis, and Pharmacological Characterization of Substituted Quinoxalines as NOP Receptor Ligands.

Design, Synthesis, and Pharmacological Characterization of Substituted Quinoxalines as NOP Receptor Ligands.

Journal: Current medicinal chemistry

Published: March 13, 2025

Molecular design and evaluation of aza-polycyclic carbamoyl pyridones as HIV-1 integrase strand transfer inhibitors.

Molecular design and evaluation of aza-polycyclic carbamoyl pyridones as HIV-1 integrase strand transfer inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: April 25, 2024

New designs for HIV-1 integrase inhibitors: a patent review (2018-present).

New designs for HIV-1 integrase inhibitors: a patent review (2018-present).

Journal: Expert opinion on therapeutic patents

Published: February 08, 2023

Structure-activity relationship studies of anti-bunyaviral cap-dependent endonuclease inhibitors.

Structure-activity relationship studies of anti-bunyaviral cap-dependent endonuclease inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: December 21, 2022

Identification of cap-dependent endonuclease inhibitors with broad-spectrum activity against bunyaviruses.

Identification of cap-dependent endonuclease inhibitors with broad-spectrum activity against bunyaviruses.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 29, 2022

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.

Journal: Journal of medicinal chemistry

Published: March 30, 2022

Discovery of tricyclic HIV-1 integrase-LEDGF/p75 allosteric inhibitors by intramolecular direct arylation reaction.

Discovery of tricyclic HIV-1 integrase-LEDGF/p75 allosteric inhibitors by intramolecular direct arylation reaction.

Journal: Bioorganic & medicinal chemistry letters

Published: December 26, 2021

Discovery of novel HIV-1 integrase-LEDGF/p75 allosteric inhibitors based on a pyridine scaffold forming an intramolecular hydrogen bond.

Discovery of novel HIV-1 integrase-LEDGF/p75 allosteric inhibitors based on a pyridine scaffold forming an intramolecular hydrogen bond.

Journal: Bioorganic & medicinal chemistry letters

Published: October 09, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026